Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Transcutaneous Pulsed Radiofrequency Targeting the Tibial Nerve Versus Radial Extracorporeal Shock Wave Therapy for Painful Calcaneal Spur: a Randomized Controlled Trial

6 november 2026 uppdaterad av: Halil Ibrahim Altun

Heel pain is a common musculoskeletal complaint that can substantially impair daily activities and reduce patients' quality of life. Calcaneal spurs are frequently associated with plantar heel pain, although the presence of a spur does not necessarily indicate that it is the direct source of symptoms. Treatment is generally conservative and may include activity modification, stretching exercises, orthoses, analgesics, and physical therapy modalities. However, some patients continue to experience symptoms despite these interventions.

Extracorporeal shock wave therapy (ESWT) is an established non-invasive treatment option for persistent plantar heel pain and plantar fasciopathy. It delivers acoustic pressure waves to the target tissue and is thought to exert its therapeutic effects through mechanotransduction, vascular responses, tissue remodeling, and modulation of nociceptive signaling.

Pulsed radiofrequency (PRF) is a neuromodulatory technique that delivers intermittent radiofrequency energy while limiting thermal tissue damage. Its proposed mechanisms include modulation of nociceptive transmission and neural signaling rather than intentional nerve destruction. Transcutaneous pulsed radiofrequency (TCPRF) provides a non-invasive approach by delivering radiofrequency energy through surface electrodes, without the need for needle insertion.

Although radiofrequency-based interventions and ESWT have been investigated separately in patients with painful calcaneal spurs and plantar heel pain, clinical evidence regarding TCPRF targeting the posterior tibial nerve remains limited. This randomized controlled trial compared the effects of TCPRF applied over the posterior tibial nerve with radial ESWT in patients with symptomatic calcaneal spurs. Pain intensity, foot-related function, and analgesic consumption were evaluated over a three-month follow-up period.

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Detaljerad beskrivning

This prospective, single-center, randomized controlled trial was conducted between September 2024 and April 2025 in the Pain Medicine and Physical Medicine and Rehabilitation departments of the University of Health Sciences Istanbul Kanuni Sultan Suleyman Training and Research Hospital. A total of 55 patients aged 18-65 years with symptomatic, radiologically confirmed calcaneal spurs who had not responded adequately to conservative treatment were enrolled.

Following confirmation of eligibility and provision of written informed consent, participants were assigned to one of two treatment groups using a computer-generated randomization sequence: the TCPRF group (n = 29) or the radial ESWT group (n = 26). The sample size calculation was performed using G*Power version 3.1.9.4, with a two-sided significance level of 0.05, statistical power of 90%, and an effect size of 0.85 based on pain intensity data from a previous randomized trial of TCPRF. The calculated minimum sample sizes were 28 participants for the TCPRF group and 24 for the ESWT group.

In the TCPRF group, treatment was administered by an experienced pain medicine specialist under standard monitoring, including non-invasive blood pressure measurement, pulse oximetry, and electrocardiography. Participants were placed in the supine position. A 45 × 98 mm transcutaneous electrode (FIAB SPA, Italy) was positioned at the ankle, posterior to the medial malleolus, along the course of the posterior tibial nerve and adjacent to the posterior tibial artery, which was identified by palpation. TCPRF was delivered at 80 V, 2 Hz, and a pulse duration of 20 ms for 8 minutes. The treatment was administered once weekly for a total of three sessions.

In the ESWT group, radial extracorporeal shock wave therapy was delivered using an electro-pneumatic device (Vibrolith Orto®). All sessions were administered by the same physiotherapist under the supervision of a physical medicine and rehabilitation specialist with at least 10 years of experience in ESWT prescription. Participants were positioned prone, and radial shock waves were applied to the calcaneal spur region using the following parameters: 10 Hz, 2,000 impulses, and 2.5 bar. Treatment was administered once weekly for a total of three sessions.

Participants in both groups received standardized instructions regarding a home exercise program that included foot and plantar fascia stretching exercises. Paracetamol was permitted as the only rescue analgesic during the follow-up period; the use of other analgesics, including non-steroidal anti-inflammatory drugs, was discouraged.

Treatment outcomes were assessed by an independent pain medicine specialist who was blinded to treatment allocation. Demographic and clinical data, including age, sex, body mass index, symptom duration, comorbidities, concomitant medical treatments, and the treated side, were recorded at baseline. Pain intensity was assessed using the Visual Analogue Scale (VAS), a 10-cm scale ranging from 0 (no pain) to 10 (the worst pain imaginable). Participants were asked to indicate their average heel pain during the preceding week. Foot-related function was evaluated using the Foot Function Index (FFI), a validated 23-item questionnaire comprising three domains: pain, disability, and activity limitation. Higher FFI scores indicate greater functional impairment. Mean daily paracetamol consumption was also recorded in milligrams per day.

VAS scores, FFI scores, and daily paracetamol consumption were evaluated at baseline (T0), one month (T1), and three months (T3) after treatment. The FFI was prespecified as the primary outcome, while VAS pain scores and mean daily paracetamol consumption were considered secondary outcomes.

Studietyp

Interventionell

Inskrivning (Faktisk)

55

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Istanbul, Turkiet (Türkiye), 34000
        • Kanuni Sultan Süleyman Training and Research Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 65 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria

Patients aged 18-65 years.

Patients diagnosed with calcaneal spur based on medical history, clinical examination, and radiological findings, who had not responded adequately to conservative treatment.

Patients who provided written informed consent to participate in the study.

Exclusion Criteria

Patients who had undergone any interventional procedure for calcaneal spur within the preceding 6 months.

Patients with morbid obesity (body mass index > 35 kg/m²).

Patients with advanced decompensated heart failure or an implanted cardiac pacemaker.

Patients with a known allergy to transcutaneous electrodes or pads.

Patients with skin infection at the ESWT application site or the transcutaneous electrode placement site.

Patients with metal implants.

Patients with circulatory disorders or skin lesions in the treatment area.

Patients unable to communicate adequately or maintain the required treatment position.

Patients with bleeding disorders.

Patients with active psychosis, progressive neurological deficits, or neuromuscular disorders.

Pregnant women.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Övrig: Neuromodulering av den bakre tibialisnerven i hälsporren (Epin Calcanei)

Instead of invasive application of PRF directly to the lesion area or nerve, transcutaneous pulsed radiofrequency (TCPRF) is applied noninvasively.

Övrig: extrakorporeal stötvågsterapi (ESWT)

A shock wave is created together with sound and pressure waves. Changes at the cellular level with the shock wave include increased collagen production, increased blood flow in the applied area, acceleration of wound healing and cellular proliferation.

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Visual Analogue Scale
Tidsram: three months
three months
Foot Function Index
Tidsram: three months
three months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Huvudutredare: halil ibrahim altun, specialist, Kanuni Sultan Süleyman Training and Research Hospital

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 september 2024

Primärt slutförande (Faktisk)

20 november 2024

Avslutad studie (Faktisk)

30 april 2025

Studieregistreringsdatum

Först inskickad

12 augusti 2024

Först inskickad som uppfyllde QC-kriterierna

14 augusti 2024

Första postat (Faktisk)

16 augusti 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

12 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

6 november 2026

Senast verifierad

1 september 2025

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • heelspur

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .